Pharmaceuticals & Therapeutics

DEWAR'S new U.S. Open whisky isn't just a spirit; it's a story of place, blending Scottish heritage with Long Island wine casks from Wölffer Estate.

A new firm, Nortiva Bio, is launching with tech from MIT to turn daily pills into monthly doses, starting with a contraceptive backed by the Gates Foundation.

A new grant from The Michael J. Fox Foundation highlights a radical approach to Parkinson's: targeting astrocytes to restore balance and halt neurodegeneration.

Goldfish Swim School's new 'Dads & Minis' program is more than a swim class; it's a strategic move to engage fathers, combat drowning stats, and innovate.

Companies like eGenesis are turning science fiction into reality with gene-edited pig organs. This is the story of a medical revolution at a crossroads.

New detachable sensor leads from Monnit allow for instant recertification, eliminating costly downtime in pharma and healthcare while ensuring data integrity.

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

Memo Therapeutics' Potravitug shows promise in a Phase II trial, offering the first real weapon against a common virus that threatens kidney transplants.

A massive conditional loan from the Pentagon's investment arm aims to transform a Utah uranium mill into a cornerstone of America's critical minerals strategy.

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

A new spray-dried plasma could end reliance on freezers, transforming trauma care from the battlefield to rural ERs. But can Velico navigate the path to market?

RedHill Biopharma's new financing provides crucial cash, but the real story is in the warrants and the hunt for a strategic acquisition. A deep dive.

As Lindsay Corp prepares its Q3 report, investors are watching how the firm balances weak farm sentiment against rising demand for water-saving tech.

As CFO Dave Denton departs for the consumer goods sector, Pfizer taps a 20-year veteran for the interim role, signaling continuity amid a crucial post-acquisition phase.

A Filipino student's award-winning bathroom design highlights a major market shift. LIXIL's American Standard is capitalizing on the multigenerational home trend.

With regulatory approval for its Covelya Group acquisition, Kraken Robotics is creating a subsea giant, set to redefine ocean exploration and defense.

Beyond a simple merger, Conrex Group's acquisition of Formweld Fitting signals a strategic shift toward creating a resilient, one-stop industrial giant.

Early trial data for a novel antibody-drug conjugate shows a 32% response rate in a hard-to-treat patient group, signaling a potential new front in precision oncology.

After three decades, a new class of therapy for a rare liver disease lands in Singapore, rewriting the rules of care by targeting patient suffering, not just lab results.